FDA Inspection 1191253 — Glaxo Wellcome Manufacturing Pte Limited
The FDA completed an inspection of Glaxo Wellcome Manufacturing Pte Limited on Sep 2, 2022 in Singapore. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 2, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Singapore (Singapore)